Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: physical function

Guselkumab Studied to Treat RA, Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  September 15, 2015

Guselkumab Studied to Treat RA & Plaque Psoriasis Guselkumab (GUS) is a subcutaneously administered monoclonal antibody that targets interleukin (IL) 23.1 It is being investigated in a Phase 2 study to treat rheumatoid arthritis (RA) and moderate to severe plaque psoriasis (PsA). On June 11, 2015, at the 2015 meeting of the European League Against…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:Biosimilarsclinical trialsDrugsguselkumaboutcomeplaque psoriasisRheumatoid arthritisrheumatologySafety

EULAR 2015: Emerging Concepts, Treatments for Axial Spondyloarthritis

Thomas R. Collins  |  September 15, 2015

ROME, Italy—When it comes to thinking about disease modification—a main goal in the treatment of axial spondyloarthritis (axial SpA) and other inflammatory diseases—it’s time to reconsider the concept, an expert said at EULAR 2015, the annual congress of the European League Against Rheumatism (EULAR). The traditional way of assessing disease modification, inhibiting radiographic progression, is…

Filed under:Axial SpondyloarthritisConditionsMeeting Reports Tagged with:patient careTreatment

EULAR 2015: Innovations in Rheumatology Education, Practice

Susan Oliver, RN, FRCN, MSc, OBE  |  September 15, 2015

ROME, Italy—The European League Against Rheumatism (EULAR) annual congress (EULAR 2015) was a much-anticipated event, with more than 14,000 delegates attending from far and wide. The Health Professional Standing Committee was particularly delighted to have planned a program that provided the latest in research terms but also an eclectic mix of valuable topics for health…

Filed under:AppsMeeting ReportsTechnologyTechnology Tagged with:exercise therapypatient careRArheumatic and musculoskeletal disease phenotypesRheumatoid arthritisRMDTreatment

Mindfulness May Improve Medical Efficacy in Rheumatology Patients

Kimberly Retzlaff  |  September 15, 2015

Every day, rheumatology patients live with the realities of having a chronic disease that requires a lifetime of treatment. This knowledge can be an emotional burden, and some people deal with it better than others. Emerging research is showing that those patients who exhibit emotional control are better able to cope and ultimately experience a…

Filed under:ConditionsPractice Support Tagged with:Clinicalmindfulnesspatient carerheumatologyTreatment

Can We Get Closer to a Cure for RA?

Marc Feldmann & Ravinder N. Maini  |  September 1, 2015

Despite new therapeutics, progress for RA patients has virtually stalled over the past 10 years. In this article, the authors discuss many options to advance to a cure and the evidence for them, including the combination of low-dose methotrexate and anti-TNF; targeting angiogenesis and tissue damage pathways directly; antigen-specific therapy; potential combination of TNF and IL17 blockade; and targeting inhibitory receptors and regulatory T cells.

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis & Rheumatologycombination therapycureDrugsRheumatoid Arthritis (RA)

Biosimilar Drugs for RA Studied in Multiple Trials

Michele B. Kaufman, PharmD, BCGP  |  August 17, 2015

Etanercept Biosimilars A number of Phase 3 trials are ongoing for etanercept biosimilars.1 One evaluation identified three trials in rheumatoid arthritis (RA) patients and one in psoriasis patients. The psoriatic arthritis trial evaluated PASI as a primary endpoint and the following secondary endpoints: PASI50, PASI75, PASI90, PASI score, laboratory values, ECG, adverse events (AEs), injection…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:Biosimilarsclinical trialsDrugsoutcomeRheumatoid arthritisrheumatologySafety

Knee Surgery for Pain May Not Be Worthwhile

Lisa Rapaport  |  July 9, 2015

(Reuters Health)—Middle-aged and older adults with torn cartilage or painful arthritis in their knee are not likely to benefit from arthroscopic surgery, and could be harmed by it, a review of past studies hints. Researchers reviewed nine previous studies with a combined 1,270 patients and found the surgery no better than other options like exercise…

Filed under:Conditions Tagged with:kneeKnee Osteoarthritis (OA)PainRheumatiod arthritissurgery

Biosimilar Drug Updates Reported from EULAR

Michele B. Kaufman, PharmD, BCGP  |  July 8, 2015

At the 2015 meeting of the European League Against Rheumatism in June, multiple studies were presented comparing the use of different biosimilar and biologic drugs in treating rheumatoid arthritis…

Filed under:Biologics/DMARDsDrug UpdatesEULAR/OtherMeeting Reports Tagged with:adalimumabBiologics & BiosimilarsetanerceptEULARRheumatiod arthritis

Knee Osteoarthritis Pain Worse with Insomnia

Lisa Rapaport  |  June 18, 2015

(Reuters Health)—People suffering from osteoarthritis, the most common type of joint inflammation, are more likely to have knee pain when they also have difficulty getting enough sleep, a study suggests. Researchers found that people with knee osteoarthritis and insomnia were also more likely to suffer from a nervous system disorder called “central sensitization” that makes…

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:Arthritis Care & Researchinsomniaknee osteoarthritisPainpatient care

Biosimilars for RA Studied in Multiple Trials

Michele B. Kaufman, PharmD, BCGP  |  June 17, 2015

Biosimilars for etanercept and sarilumab are being examined in multiple Phase 3 trials for their effects in RA and psoriasis patients.

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic ArthritisRheumatoid Arthritis Tagged with:Biosimilarsclinical trialsPsoriatic Arthritis

  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 80
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences